99mTc-macroaggregated albumin poorly predicts the intrahepatic distribution of 90Y resin microspheres in hepatic radioembolization

Journal of Nuclear Medicine

Volumn 54, Issue 8, 2013, Pages 1294-1301

  Wondergem, Maurits ^a   Smits, Maarten L J ^a   Elschot, Mattijs ^a   De Jong, Hugo W A M ^a   Verkooijen, Helena M ^a   Van Den Bosch, Maurice A A J ^a   Nijsen, Johannes F W ^a   Lam, Marnix G E H ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

90Y microspheres; 99mTc MAA; Dosimetry; Liver; Radioembolization

Indexed keywords

MACROSALB TC 99M; MICROSPHERE Y 90; RADIOACTIVE MICROSPHERE; SIR SPHERES; TECHNESCAN LYOMAA; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; MICROSPHERE; RESIN; YTTRIUM;

ACCURACY; ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; CLINICAL ARTICLE; COIL EMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; LIVER RESECTION; LIVER TUMOR; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PRIORITY JOURNAL; RADIOACTIVITY; RADIOEMBOLIZATION; RADIOFREQUENCY ABLATION; RETROSPECTIVE STUDY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTEMIC THERAPY; 90Y MICROSPHERES; 99MTC-MAA; CHEMISTRY; DOSIMETRY; LIVER; METABOLISM; MIDDLE AGED; RADIATION EXPOSURE; SCINTISCANNING;

90Y MICROSPHERES; 99MTC-MAA; DOSIMETRY; LIVER; RADIOEMBOLIZATION;

ADULT; AGED; EMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; LIVER; MALE; MICROSPHERES; MIDDLE AGED; RESINS, SYNTHETIC; RETROSPECTIVE STUDIES; TECHNETIUM TC 99M AGGREGATED ALBUMIN; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; YTTRIUM RADIOISOTOPES;

EID: 84881436167     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.117614     Document Type: Article

References (38)

1. Kennedy A, Coldwell D, Sangro B, Wasan H, Salem R. Radioembolization for the treatment of liver tumors: general principles. Am J Clin Oncol. 2012;35:91-99.
2. Sangro B, Salem R, Kennedy A, Coldwell D, Wasan H. Radioembolization for hepatocellular carcinoma: a review of the evidence and treatment recommendations. Am J Clin Oncol. 2011;34:422-431.
3. Coldwell D, Sangro B, Salem R, Wasan H, Kennedy A. Radioembolization in the treatment of unresectable liver tumors: experience across a range of primary cancers. Am J Clin Oncol. 2012;35:167-177.
4. Lewandowski RJ, Sato KT, Atassi B, et al. Radioembolization with 90Y microspheres: angiographic and technical considerations. Cardiovasc Intervent Radiol. 2007;30:571-592.
5. Dezarn WA, Cessna JT, DeWerd LA, et al. Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for 90Y microsphere brachytherapy in the treatment of hepatic malignancies. Med Phys. 2011;38:4824-4845.
6. Lenoir L, Edeline J, Rolland Y, et al. Usefulness and pitfalls of MAA SPECT/CT in identifying digestive extrahepatic uptake when planning liver radioembolization. Eur J Nucl Med Mol Imaging. 2012;39:872-880.
7. Ho S, Lau WY, Leung TW, et al. Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours. Eur J Nucl Med. 1996;23:947-952.
8. Ho S, Lau WY, Leung TW, et al. Tumour-to-normal uptake ratio of 90Y microspheres in hepatic cancer assessed with 99Tcm macroaggregated albumin. Br J Radiol. 1997;70:823-828.
9. Ho S, Lau WY, Leung TW, Chan M, Johnson PJ, Li AK. Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med. 1997;24:293-298.
10. Lau WY, Kennedy AS, Kim YH, et al. Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres. Int J Radiat Oncol Biol Phys. 2012;82:401-407.
11. Kao YH, Hock Tan AE, Burgmans MC, et al. Image-guided personalized predictive dosimetry by artery-specific SPECT/CT partition modeling for safe and effective 90Y radioembolization. J Nucl Med. 2012;53:559-566.
12. Jiang M, Fischman A, Nowakowski FS, et al. Segmental perfusion differences on paired tc-99m macroaggregated albumin (MAA) hepatic perfusion imaging and yttrium-90 (Y-90) bremsstrahlung imaging studies in SIR-sphere radioembolization: associations with angiography. J Nucl Med Radiat Ther. 2012;3:122.
13. Kennedy A, Nag S, Salem R, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys. 2007;68:13-23.
14. Elschot M, Nijsen JF, Dam AJ, de Jong HW. Quantitative evaluation of scintillation camera imaging characteristics of isotopes used in liver radioembolization. PLoS ONE. 2011;6:e26174.
15. Bismuth H. Surgical anatomy and anatomical surgery of the liver. World J Surg. 1982;6:3-9.
16. Bol GH, Kotte AN, van der Heide UA, Lagendijk JJ. Simultaneous multimodality ROI delineation in clinical practice. Comput Methods Programs Biomed. 2009;96:133-140.
17. Gulec SA, Mesoloras G, Stabin M. Dosimetric techniques in 90Y-microsphere therapy of liver cancer: the MIRD equations for dose calculations. J Nucl Med. 2006;47:1209-1211.
18. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307-310.
19. Bland JM, Altman DG. Comparing methods of measurement: why plotting difference against standard method is misleading. Lancet. 1995;346:1085-1087.
20. 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results. J Nucl Med. 2012;53:255-263.
21. 99mTc)-macroaggregated albumin SPECT images for planning 90Y therapy of liver cancer. Technol Cancer Res Treat. 2010;9:253-262.
22. BarentszMW, VenteMA, LamMG, et al. Technical solutions to ensure safe yttrium-90 radioembolization in patients with initial extrahepatic deposition of 99mtechnetiumalbumin macroaggregates. Cardiovasc Intervent Radiol. 2011;34:1074-1079.
23. Kao YH, Tan EH, Teo TK, Ng CE, Goh SW. Imaging discordance between hepatic angiography versus Tc-99m-MAA SPECT/CT: a case series, technical discussion and clinical implications. Ann Nucl Med. 2011;25:669-676.
24. Kennedy AS, Kleinstreuer C, Basciano CA, Dezarn WA. Computer modeling of yttrium-90-microsphere transport in the hepatic arterial tree to improve clinical outcomes. Int J Radiat Oncol Biol Phys. 2010;76:631-637.
25. Basciano CA, Kleinstreuer C, Kennedy AS, Dezarn WA, Childress E. Computer modeling of controlled microsphere release and targeting in a representative hepatic artery system. Ann Biomed Eng. 2010;38:1862-1879.
26. Rose SC, Kikolski SG, Chomas JE. Downstream hepatic arterial blood pressure changes caused by deployment of the Surefire AntiReflux expandable tip. Cardiovasc Intervent Radiol. December 19, 2012 [Epub ahead of print].
27. Bult W, Vente MA, Zonnenberg BA, Van Het Schip AD, Nijsen JF. Microsphere radioembolization of liver malignancies: current developments. Q J Nucl Med Mol Imaging. 2009;53:325-335.
28. SIR-Spheres Yttrium-90 Resin Microspheres [package insert]. Woburn, MA: Sirtex Medical Inc. 2013.
29. Lewandowski RJ, Riaz A, Ryu RK, et al. Optimization of radioembolic effect with extended-shelf-life yttrium-90 microspheres: results from a pilot study. J Vasc Interv Radiol. 2009;20:1557-1563.
30. Lhommel R, van Elmbt L, Goffette P, et al. Feasibility of 90Y TOF PET-based dosimetry in liver metastasis therapy using SIR-Spheres. Eur J Nucl Med Mol Imaging. 2010;37:1654-1662.
31. Gates VL, Esmail AA, Marshall K, Spies S, Salem R. Internal pair production of 90Y permits hepatic localization of microspheres using routine PET: proof of concept. J Nucl Med. 2011;52:72-76.
32. Kao YH, Tan EH, Ng CE, Goh SW. Yttrium-90 time-of-flight PET/CT is superior to Bremsstrahlung SPECT/CT for postradioembolization imaging of microsphere biodistribution. Clin Nucl Med. 2011;36:e186-e187.
33. Smits ML, Nijsen JF, van den Bosch MA, et al. Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study. Lancet Oncol. 2012;13:1025-1034.
34. Nijsen JF, Zonnenberg BA, Woittiez JR, et al. Holmium-166 poly lactic acid microspheres applicable for intra-arterial radionuclide therapy of hepatic malignancies: effects of preparation and neutron activation techniques. Eur J Nucl Med Mol Imaging. 1999;26:699-704.
35. Zielhuis SW, Nijsen JF, Seppenwoolde JH, et al. Lanthanide bearing microparticulate systems for multi-modality imaging and targeted therapy of cancer. Curr Med Chem Anticancer Agents. 2005;5:303-313.
36. Zielhuis SW, Nijsen JF, de Roos R, et al. Production of GMP-grade radioactive holmium loaded poly(L-lactic acid) microspheres for clinical application. Int J Pharm. 2006;311:69-74.
37. Seevinck PR, Seppenwoolde JH, de Wit TC, et al. Factors affecting the sensitivity and detection limits of MR imaging, CT, and SPECT for multimodal diagnostic and therapeutic agents. Anticancer Agents Med Chem. 2007;7:317-334.
38. van de Maat GH, Seevinck PR, Elschot M, et al. MR imaging-based biodistribution assessment of holmium-166 poly(L-lactic acid) microspheres after radioembolisation. Eur Radiol. 2013;23:827-835.